Cell Therapy Growth Factor - Worldwide

The global cell therapy growth factor market size accounted for USD 668 million in 2024 and is expected to exceed around USD 1,389.63 million by 2034, growing at a CAGR of 7.6% from 2024 to 2034.

The rise in chronic diseases around the world is expected to drive the growth of the cell therapy growth factor market in the coming years. Cell therapies are a promising treatment and have the potential to transform the lives of people living with chronic diseases such as cancer, diabetes, autoimmune diseases, and others. Cell therapies have given meaningful benefits to some patients living with cancer, solid tumors, and autoimmune diseases. Several researchers are increasingly focusing on discovering more about the potential uses of cell therapy to treat various medical ailments.

The surge in cell therapies by regulatory agencies such as the FDA (Food and Drug Administration) and EMA (European Medicines Agency) to manage chronic diseases, offers significant growth opportunities to the market.

According to the IQVIA report in March 2024:

• Expenses on cell and gene therapies are substantially rising over the period and reached USD 5.9 billion in 2023, rising 38 percent from 2022 although spending accounted for only 0.4% of the USD 1.6Tn spent on medicines globally in 2023.
• As of the end of 2023, 76 cell and gene therapies have been launched worldwide, more than double the number of therapies that had been launched by 2013.
• In the last five years, 3,285 trials were started to evaluate cell and gene therapies in patients across all sponsor types, including 631 in 2023.